Belite Bio, Inc.(BLTE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BLTE Belite Bio, Inc.

未开盘 03-23 16:00:00 EDT

151.14

-3.45

-2.23%

盘后151.14

+0.000.00%

18:41 EDT

最高158.68	最低150.14	成交量15.38万
今开155.45	昨收154.59	日振幅5.52%
总市值59.46亿	流通市值28.36亿	总股本3,934万
成交额2,344万	换手率0.82%	流通股本1,876万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BLTE","market":"US","secType":"STK","nameCN":"Belite Bio, Inc.","latestPrice":151.14,"timestamp":1774296000000,"preClose":154.59,"halted":0,"volume":153809,"hourTrading":{"tag":"盘后","latestPrice":151.14,"preClose":151.14,"latestTime":"18:41 EDT","volume":192,"amount":29272.3,"timestamp":1774305697174,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.022317096836794212,"floatShares":18761200,"shares":39340000,"eps":-2.31411,"marketStatus":"未开盘","change":-3.45,"latestTime":"03-23 16:00:00 EDT","open":155.45,"high":158.68,"low":150.14,"amount":23437989.127570003,"amplitude":0.055243,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.31411,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774339200000},"marketStatusCode":0,"adr":0,"adrRate":1,"listingDate":1651204800000,"exchange":"NASDAQ","adjPreClose":154.59,"postHourTrading":{"tag":"盘后","latestPrice":151.14,"preClose":151.14,"latestTime":"18:41 EDT","volume":192,"amount":29272.3,"timestamp":1774305697174,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.872764},"requestUrl":"/m/hq/s/BLTE","defaultTab":"news","newsList":[{"id":"1110799050","title":"Belite Bio公布2025年第四季度及全年初步未经审计财务业绩并更新公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1110799050","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110799050?lang=zh_cn&edition=full","pubTime":"2026-03-02 19:01","pubTimestamp":1772449273,"startTime":"0","endTime":"0","summary":"Belite Bio, Inc.公布了其2025年第四季度及全年的初步未经审计财务业绩，并同步提供了公司业务的最新进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1108971152","title":"Belite Bio完成针对斯特格特病变的Tinlarebant药物DRAGON II临床试验患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1108971152","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108971152?lang=zh_cn&edition=full","pubTime":"2026-01-27 21:01","pubTimestamp":1769518872,"startTime":"0","endTime":"0","summary":"Belite Bio, Inc.（纳斯达克代码：BLTE）近日宣布，其针对斯特格特病变1型（Stgd1）研发的候选药物Tinlarebant，已顺利完成名为“DRAGON II”的临床试验的患者入组工作。这项关键性研究的推进，标志着公司在治疗这种罕见眼科疾病领域取得了重要阶段性成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"1175520160","title":"Belite Bio获美银环球研究首次覆盖 给予买入评级及195美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1175520160","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175520160?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:08","pubTimestamp":1769429291,"startTime":"0","endTime":"0","summary":"美银环球研究(BofA Global Research)宣布对Belite Bio, Inc.启动覆盖研究，并给予该公司\"买入\"评级，同时设定目标股价为195.00美元。\n此次覆盖标志着这家知名研究机构对Belite Bio未来发展前景的积极看好。195美元的目标价显示出分析师对公司价值成长空间的乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1192110803","title":"Belite Bio宣布以3.5亿美元定价的承销公开发行美国存托股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1192110803","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192110803?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:38","pubTimestamp":1764646705,"startTime":"0","endTime":"0","summary":"Belite Bio宣布以3.5亿美元定价的承销公开发行美国存托股份","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1168494999","title":"曾被视为无法治愈疾病患者的新希望：Belite Bio公布针对青少年Stargardt病的关键全球第三阶段Dragon试验Tinlarebant的积极初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1168494999","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168494999?lang=zh_cn&edition=full","pubTime":"2025-12-01 19:01","pubTimestamp":1764586886,"startTime":"0","endTime":"0","summary":"曾被视为无法治愈疾病患者的新希望：Belite Bio公布针对青少年Stargardt病的关键全球第三阶段Dragon试验Tinlarebant的积极初步结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1181287053","title":"Belite Bio宣布英国MHRA同意Tinlarebant治疗Stargardt病的有条件市场授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1181287053","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181287053?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:21","pubTimestamp":1763569310,"startTime":"0","endTime":"0","summary":"11月2日 - Belite Bio Inc.宣布，英国药品和健康产品监管局（MHRA）已同意其基于中期分析结果提出的有条件市场授权申请，以使用Tinlarebant治疗Stargardt病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1183806485","title":"异动解读 | Belite Bio盘中大涨5.43%，分析师上调目标价至140美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183806485","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183806485?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:34","pubTimestamp":1762958079,"startTime":"0","endTime":"0","summary":"11月12日，生物科技公司Belite Bio(股票代码:BLTE)股价盘中大涨5.43%，引发市场关注。\n\n消息面上，投资银行Maxim Group将Belite Bio的目标价从110美元大幅上调至140美元。分析师的看好态度显然提振了投资者信心，推动公司股价上涨。\n\nBelite Bio是一家专注于开发用于治疗眼科和代谢性疾病的新型疗法的临床阶段生物制药公司。目标价的上调表明分析师看好公司的研发管线和未来发展前景。不过，投资者仍需关注该公司的临床试验进展和财务状况等基本面因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BLTE"],"gpt_icon":0},{"id":"2580764702","title":"Belite Bio Inc盘中异动 早盘股价大涨5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580764702","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580764702?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:39","pubTimestamp":1762180757,"startTime":"0","endTime":"0","summary":"北京时间2025年11月03日22时39分，Belite Bio Inc股票出现异动，股价快速上涨5.21%。截至发稿，该股报111.42美元/股，成交量1.1266万股，换手率0.03%，振幅3.48%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，Phio Pharmaceuticals Corp.、Tharimmune, Inc.、Terns Pharmaceuticals, Inc.涨幅较大，Phio Pharmaceuticals Corp.、Tharimmune, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为1527.64%、375.62%、346.04%，振幅较大的相关个股有Ethzilla Corporation C/Wts 06/11/2025、Tharimmune, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为63.35%、61.36%、52.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103223918a485690b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103223918a485690b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"1186565995","title":"Belite Bio宣布英国药品和医疗产品监管局同意根据Tinlarebant治疗Stargardt病的中期分析结果申请有条件市场授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1186565995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186565995?lang=zh_cn&edition=full","pubTime":"2025-11-02 22:01","pubTimestamp":1762092073,"startTime":"0","endTime":"0","summary":"Belite Bio宣布英国药品和医疗产品监管局同意根据Tinlarebant治疗Stargardt病的中期分析结果申请有条件市场授权","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1133872821","title":"Belite Bio宣布中国NMPA同意Tinlarebant治疗Stargardt病的新药申请，并优先审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1133872821","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133872821?lang=zh_cn&edition=full","pubTime":"2025-10-15 20:01","pubTimestamp":1760529683,"startTime":"0","endTime":"0","summary":"Belite Bio宣布，中国国家药品监督管理局（NMPA）已同意其针对Tinlarebant治疗Stargardt病的新药申请，并将根据中期分析结果进行优先审查。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2518210273","title":"Belite Bio Inc盘中异动 早盘大幅上涨6.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518210273","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518210273?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613476,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Belite Bio Inc股票出现波动，股价大幅上涨6.03%。截至发稿，该股报67.00美元/股，成交量1162股，换手率0.00%，振幅0.00%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.59%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213117964035a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213117964035a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2517602164","title":"Belite Bio Inc盘中异动 快速拉升5.30%报60.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517602164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517602164?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:53","pubTimestamp":1741110821,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日01时53分，Belite Bio Inc股票出现波动，股价大幅拉升5.30%。截至发稿，该股报60.20美元/股，成交量2.2093万股，换手率0.07%，振幅6.12%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.28%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015342989bdd5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015342989bdd5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2516652728","title":"Belite Bio Inc盘中异动 下午盘快速拉升5.23%报60.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516652728","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516652728?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:49","pubTimestamp":1741027758,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时49分，Belite Bio Inc股票出现波动，股价急速拉升5.23%。截至发稿，该股报60.19美元/股，成交量3.8615万股，换手率0.12%，振幅4.15%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为0.61%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304024918989a496c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304024918989a496c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2516374952","title":"Belite Bio Inc盘中异动 临近午盘股价大跌5.11%报55.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516374952","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516374952?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:46","pubTimestamp":1740761160,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时46分，Belite Bio Inc股票出现波动，股价大幅跳水5.11%。截至发稿，该股报55.29美元/股，成交量3.3522万股，换手率0.11%，振幅4.96%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为0.31%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301004601abe10a5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301004601abe10a5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2514638304","title":"Belite Bio Inc盘中异动 股价大涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514638304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514638304?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:32","pubTimestamp":1740666769,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时32分，Belite Bio Inc股票出现波动，股价大幅上涨5.32%。截至发稿，该股报58.45美元/股，成交量1.5494万股，换手率0.05%，振幅1.80%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为0.31%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223249abdf6ef6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223249abdf6ef6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2510323337","title":"Belite Bio Inc盘中异动 大幅上涨5.95%报57.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510323337","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510323337?lang=zh_cn&edition=full","pubTime":"2025-02-12 01:21","pubTimestamp":1739294494,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日01时21分，Belite Bio Inc股票出现波动，股价快速上涨5.95%。截至发稿，该股报57.00美元/股，成交量9139股，换手率0.03%，振幅5.24%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为1.89%。其相关个股中，Omega Therapeutics, Inc.、Oramed Pharmaceuticals Inc.、Dominari Holdings Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为3036.61%、1356.45%、446.63%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、59.46%、58.60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212012135961f64d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212012135961f64d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2510896990","title":"Belite Bio Inc盘中异动 股价大跌5.23%报54.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510896990","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510896990?lang=zh_cn&edition=full","pubTime":"2025-02-11 02:39","pubTimestamp":1739212789,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日02时39分，Belite Bio Inc股票出现波动，股价急速跳水5.23%。截至发稿，该股报54.52美元/股，成交量2.6437万股，换手率0.08%，振幅4.94%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.34%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211023949961e2ee2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211023949961e2ee2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2506846975","title":"Belite Bio Inc盘中异动 快速跳水5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506846975","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506846975?lang=zh_cn&edition=full","pubTime":"2025-01-28 03:54","pubTimestamp":1738007669,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日03时54分，Belite Bio Inc股票出现异动，股价大幅跳水5.08%。截至发稿，该股报56.40美元/股，成交量1.3259万股，换手率0.04%，振幅4.21%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为0.74%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128035430abba9f5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128035430abba9f5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2505520607","title":"Benchmark：维持Belite Bio(BLTE.US)评级，由买入调整至买入评级, 目标价由57.00美元调整至79.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2505520607","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505520607?lang=zh_cn&edition=full","pubTime":"2025-01-22 00:55","pubTimestamp":1737478539,"startTime":"0","endTime":"0","summary":"Benchmark：维持Belite Bio(BLTE.US)评级，由买入调整至买入评级, 目标价由57.00美元调整至79.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/22005547678767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BLTE"],"gpt_icon":0},{"id":"2505272861","title":"Belite Bio Inc盘中异动 早盘股价大涨5.89%报59.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505272861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505272861?lang=zh_cn&edition=full","pubTime":"2025-01-21 22:46","pubTimestamp":1737470777,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时46分，Belite Bio Inc股票出现波动，股价快速拉升5.89%。截至发稿，该股报59.52美元/股，成交量7468股，换手率0.02%，振幅4.34%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为1.12%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121224617960bbc5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121224617960bbc5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BLTE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://investors.belitebio.com","stockEarnings":[{"period":"1week","weight":-0.058},{"period":"1month","weight":-0.1111},{"period":"3month","weight":-0.009},{"period":"6month","weight":1.2021},{"period":"1year","weight":1.2824},{"period":"ytd","weight":-0.0336}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Belite Bio, Inc于2018年3月27日在开曼群岛注册成立。该公司是一家临床阶段的生物制药及药物开发公司，专注于针对目前无法治疗的眼部疾病的新疗法，这些疾病涉及有重大未满足医疗需求的视网膜变性，例如（i）萎缩性年龄相关性黄斑变性（AMD），通常称为地理萎缩（GA），或晚期干性AMD，和（ii）常染色体隐性遗传Stargardt病1型，或STGD1，这两种疾病都会导致进行性视力丧失，导致永久性失明。该公司的药物研发管道还包括一种小分子口服复方药物，用于治疗代谢性疾病，如非酒精性脂肪肝、非酒精性脂肪性肝炎、NASH、2型糖尿病、T2D和痛风。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.020711},{"month":2,"riseRate":0.75,"avgChangeRate":0.070972},{"month":3,"riseRate":0.25,"avgChangeRate":-0.074254},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.0153},{"month":5,"riseRate":0.75,"avgChangeRate":0.064631},{"month":6,"riseRate":0.25,"avgChangeRate":0.187208},{"month":7,"riseRate":1,"avgChangeRate":0.228556},{"month":8,"riseRate":0.25,"avgChangeRate":0.09699},{"month":9,"riseRate":0.5,"avgChangeRate":0.027284},{"month":10,"riseRate":0.75,"avgChangeRate":0.224047},{"month":11,"riseRate":0.75,"avgChangeRate":0.12408},{"month":12,"riseRate":0.5,"avgChangeRate":0.042173}],"exchange":"NASDAQ","name":"Belite Bio, Inc.","nameEN":"Belite Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Belite Bio, Inc.(BLTE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Belite Bio, Inc.(BLTE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Belite Bio, Inc.,BLTE,Belite Bio, Inc.股票,Belite Bio, Inc.股票老虎,Belite Bio, Inc.股票老虎国际,Belite Bio, Inc.行情,Belite Bio, Inc.股票行情,Belite Bio, Inc.股价,Belite Bio, Inc.股市,Belite Bio, Inc.股票价格,Belite Bio, Inc.股票交易,Belite Bio, Inc.股票购买,Belite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Belite Bio, Inc.(BLTE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Belite Bio, Inc.(BLTE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}